Suchergebnisse - "Patriarca, Francesca"

PubPharm (266)

1

A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma : The northern Italy experience

enthalten in: Cancer medicine | 2024

von Furlan, A. | Cea, M. | Pavan, L. | +25

2

Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas : the Italian CART-SIE study

enthalten in: Leukemia | 2024

von Chiappella, A. | Casadei, B. | Chiusolo, P. | +29

3

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies : updated consensus recommendations of the European Society for Blood and Marrow Transplantation

enthalten in: The Lancet. Haematology | 2024

von Penack, O. | Marchetti, M. | Aljurf, M. | +20

4

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

5

A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients : a report from the Triveneto Myeloma Working Group

enthalten in: Annals of hematology | 2024

von Barilà, G. | Quaglia, F. | Furlan, A. | +21

6

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma : The northern Italy experience

enthalten in: Cancer Medicine | 2024

von Furlan, A. | Cea, M. | Pavan, L. | +25

7

Stem Cells mobilization and collection in allogeneic related and unrelated donors : a single center experience with focus on plerixafor

enthalten in: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis | 2023

von Marcon, C. | Bertone, A. | Mauro, S. | +9

8

Prospective evaluation of minimal residual disease in the phase II FORTE trial : a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing

enthalten in: EClinicalMedicine | 2023

von Oliva, S. | Genuardi, E. | Paris, L. | +22

9

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

enthalten in: EClinicalMedicine | 2023

von Zamagni, E. | Oliva, S. | Gay, F. | +28

10

Antibody, cell-mediated response and infection susceptibility in allogeneic hematopoietic stem cell recipients after COVID-19 mRNA vaccination

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2023

von Pizzano, U. | Facchin, G. | Marcon, C. | +14

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[27]